STOCK TITAN
  1. Home
  2. News
  3. VXRT

Vaxart, Inc - VXRT STOCK NEWS

Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.

Vaxart, Inc. (symbol: VXRT) is a clinical-stage biotechnology company dedicated to transforming vaccine delivery through its innovative oral recombinant vaccine platform. Founded in 2004, Vaxart's primary focus is the development of vaccines in tablet form, offering a needle-free alternative that is easy to administer and store. This proprietary technology aims to revolutionize the global vaccine market, addressing common diseases such as Coronavirus, Norovirus, Seasonal Influenza, Respiratory Syncytial Virus (RSV), and Human Papillomavirus (HPV).

Headquartered in the United States, Vaxart operates in a single segment focused exclusively on the discovery and development of these groundbreaking oral recombinant protein vaccines. The company has made significant strides in the clinical development of its diverse pipeline, with several candidates currently undergoing trials. Vaxart’s oral vaccines are designed to simplify distribution and administration, potentially increasing vaccination rates and improving global health outcomes.

Recent achievements for Vaxart include the ongoing development and testing of its oral COVID-19 vaccine candidate, which has shown promise in preclinical studies and early-phase clinical trials. This innovation could play a crucial role in global vaccination efforts, especially in regions where cold-chain requirements pose logistical challenges. Other notable projects include the development of oral vaccines for Norovirus and Influenza, which are also advancing through various stages of clinical testing.

Financially, Vaxart remains focused on strategic partnerships and funding opportunities to support its research and development initiatives. The company's recent financial results for the full year ended December 31, 2023, and the first quarter ended March 31, 2024, reflect its ongoing commitment to advancing its oral vaccine candidates through clinical trials and towards regulatory approval.

For more information and the latest updates, contact Vaxart Media Relations: Mark Herr (mherr@vaxart.com, 203-517-8957) or Investor Relations: Andrew Blazier (IR@vaxart.com, 646-871-8486).

News

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Rhea-AI Summary
Vaxart, Inc. announces significant progress in preparing for a Phase 2b study evaluating its oral pill XBB COVID-19 vaccine, appoints Steven Lo as President and CEO, and reports financial results for full year 2023. The company received a $9.27 million contract for a Phase 2b clinical study against an approved mRNA vaccine. Vaxart also published preclinical data showing immune responses against multiple SARS-CoV-2 variants. In the norovirus vaccine space, the company completed enrollment in a Phase 1 study in lactating mothers and expects topline data in mid-2024. Financially, Vaxart reported $39.7 million in cash and investments as of December 31, 2023, with a net loss of $82.5 million for 2023 compared to $107.8 million in 2022. Revenue for 2023 was $7.4 million, primarily from grants and royalties. Research and development expenses decreased to $68.1 million in 2023, while general and administrative expenses were $22.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
earnings
-
News

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

Rhea-AI Summary
Vaxart, Inc. (NASDAQ: VXRT) announces a business update and financial results for the full year ending December 31, 2023. The senior management team will host a conference call on March 14, 2024, at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
conferences earnings
-
News

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

Rhea-AI Summary
Vaxart, Inc. appoints Steven Lo as President and CEO, with Michael J. Finney, Ph.D. continuing as Chairman of the Board. The new CEO brings over 25 years of experience in the biopharma industry and aims to lead the Company's transformational oral vaccine platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
management
News

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

Rhea-AI Summary
Vaxart, Inc. announces promising preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of concern. The data support the vaccine platform's potential to stimulate potent mucosal cross-reactive IgA responses to multiple VOCs and reduce viral transmission. Vaxart's preparation for a Phase 2b trial of its COVID-19 XBB vaccine candidate is supported by a recent grant awarded by the United States Biomedical Advanced Research and Development Authority (BARDA). The study published in Vaccines showed that all three vaccines elicited strong cross-reactive systemic immunity and robust cross-reactive nasal and lung IgA following mucosal vaccination, as well as reduced viral replication and infectious particle shedding in immunized animals after challenge with the beta variant of SARS-CoV-2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
clinical trial
-
News

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Rhea-AI Summary
Vaxart, Inc. announced that it has been awarded $9.27 million by BARDA to fund preparation for a Phase 2b clinical study evaluating its oral pill XBB COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The study is part of the Project NextGen, a $5 billion initiative by the U.S. Department of Health and Human Services to develop innovative vaccines and therapeutics for COVID-19. Vaxart's CEO, Dr. Michael Finney, expressed excitement over the potential of their oral pill vaccine platform to revolutionize pandemic fighting and vaccination against infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
clinical trial covid-19
-
News

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

Rhea-AI Summary
Vaxart, Inc. (VXRT) has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share, generating approximately $10.0 million in gross proceeds. The net proceeds will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures. The company aims to continue advancing its oral pill vaccine platform with the goal of bringing to market oral pill vaccines that carry significant public health benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.57%
Tags
offering
News

Vaxart, Inc. Announces Management Change

Rhea-AI Summary
Vaxart, Inc. (Nasdaq: VXRT) announced the resignation of Andrei Floroiu, President and CEO, and the appointment of Michael J. Finney, Ph.D. as the Interim CEO. Dr. Finney will lead the management team through the transition while the company conducts a search for a permanent CEO. Mr. Floroiu expressed confidence in Dr. Finney's ability to advance Vaxart's oral vaccine platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.57%
Tags
none
-
News

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Rhea-AI Summary
Vaxart, Inc. (Nasdaq: VXRT) has completed enrollment and dosing in the Phase 1 clinical trial for its oral pill bivalent norovirus vaccine candidate focused on lactating mothers. The company aims to report topline data by the end of 2024. Norovirus sickens approximately 21 million people in the United States annually, with 15% of children under age 5 contracting the virus. The annual disease burden from norovirus is $10.6 billion in the U.S. alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Vaxart announces positive topline results for its oral pill vaccine candidate in reducing norovirus infection, gastroenteritis, and viral shedding. The company establishes proof of concept for its vaccine platform in two human challenge studies. Vaxart also provides updates on its norovirus and COVID-19 vaccine programs. Financial results show a net loss of $17.4 million for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
earnings
News

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Rhea-AI Summary
Vaxart, Inc. has dosed the first subject in its Phase 1 clinical trial for its oral pill bivalent norovirus vaccine candidate. The trial aims to evaluate the ability of the vaccine to induce breast milk antibodies and transfer them to young infants. Norovirus affects around 21 million people in the US annually, with 15% of children under 5 contracting the virus each year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
clinical trial

FAQ

What is the current stock price of Vaxart (VXRT)?

The current stock price of Vaxart (VXRT) is $0.6196 as of December 20, 2024.

What is the market cap of Vaxart (VXRT)?

The market cap of Vaxart (VXRT) is approximately 136.5M.

What is Vaxart, Inc. known for?

Vaxart, Inc. is known for developing oral recombinant vaccines in tablet form, targeting diseases like COVID-19, Norovirus, Influenza, RSV, and HPV.

When was Vaxart, Inc. founded?

Vaxart, Inc. was founded in 2004.

What is Vaxart's proprietary technology?

Vaxart's proprietary technology is an oral vaccine delivery platform that transforms vaccines into tablet form, eliminating the need for injections.

Where is Vaxart, Inc. headquartered?

Vaxart, Inc. is headquartered in the United States.

What are some diseases Vaxart's vaccines target?

Vaxart's vaccines target diseases including Coronavirus, Norovirus, Seasonal Influenza, Respiratory Syncytial Virus (RSV), and Human Papillomavirus (HPV).

How is Vaxart's oral vaccine beneficial?

Vaxart's oral vaccines are easy to administer, do not require needles, and simplify distribution, which can increase vaccination rates and improve global health outcomes.

What recent achievements has Vaxart made?

Recent achievements include ongoing development and testing of its oral COVID-19 vaccine candidate and advancements in oral vaccines for Norovirus and Influenza.

What is Vaxart's financial condition?

Vaxart's financial condition is focused on strategic partnerships and funding opportunities to support its research and development initiatives. Recent financial results reflect ongoing commitment to advancing vaccine candidates.

How can I contact Vaxart for more information?

For more information, contact Vaxart Media Relations: Mark Herr (mherr@vaxart.com, 203-517-8957) or Investor Relations: Andrew Blazier (IR@vaxart.com, 646-871-8486).

What segment does Vaxart operate in?

Vaxart operates in a single segment focused exclusively on the discovery and development of oral recombinant protein vaccines.

Stock VXRT logo
Vaxart, Inc

Nasdaq:VXRT

VXRT Rankings

#4177 Ranked by Market Cap
N/A Ranked by Dividends

VXRT Stock Data

136.47M
225.45M
0.87%
17.81%
4.96%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO